CHATSWORTH, Calif., Dec. 7, 2010 (GLOBE NEWSWIRE) -- IRIS International, Inc. (Nasdaq:IRIS), a leading manufacturer of automated in-vitro diagnostics systems and a provider of high value personalized medicine products and testing services, announced today that senior management will host a series of one-on-one meetings with analysts and fund managers on Tuesday, January 11, 2011, to be held at the Hilton San Francisco, 333 O'Farrell Street, San Francisco, Ca. The full day of meetings is being organized alongside the 29th Annual JP Morgan Healthcare Conference in San Francisco.
"The J.P. Morgan Annual Healthcare Conference brings together thousands of analysts, fund managers and institutions to the San Francisco Bay area and, while IRIS is not a presenting company, we believe this forum offers an excellent opportunity for IRIS to introduce the Company and provide an update to institutional investors who are planning to be in San Francisco during the conference," stated Cesar Garcia, IRIS Chairman, President and Chief Executive Officer.
Meetings with IRIS management at the Hilton San Francisco on January 11 are by invitation only. Those interested in scheduling a one-on-one, are asked to contact Ron Stabiner with The Wall Street Group at (212) 888-4848 or email, rstabiner@thewallstreetgroup.com. The Hilton SF is conveniently located in Union Square, just a few short blocks from the Westin St. Francis, the conference host hotel.
About IRIS International, Inc.
IRIS International, Inc. is a leading global in vitro diagnostics company focused on products that analyze particles and living cell forms and structures, or morphology of a variety of body fluids. The Company's products leverage its strengths in flow imaging technology, particle recognition and automation to bring efficiency to hospital and commercial laboratories. The initial applications for its technology have been in the urinalysis market and the Company is the leading worldwide provider of automated urine microscopy and chemistry systems, with an installed base of more than 2,900 systems in more than 50 countries. The Company is expanding its core imaging and morphology expertise into related markets and is developing applications in hematology and urinary tract infections. In addition, the Company recently acquired a high complexity CLIA-certified molecular pathology laboratory offering differentiated, high value molecular diagnostic services in the rapidly growing field of personalized medicine. The laboratory provides a direct commercial channel for the Company's NADiA® ultra-sensitive nucleic acid detection immunoassay platform, with applications in oncology and infectious disease. For more information, please visit www.proiris.com.